| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Opioid and opioid-like compounds and uses thereof | US13228527 | 2011-09-09 | US09776971B2 | 2017-10-03 | Edwin S. C. Wu; Mao-Hsiung Yen; Chin-Tsai Fan |
| The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage. | ||||||
| 62 | Anti-Viral Compounds | US15434789 | 2017-02-16 | US20170157105A1 | 2017-06-08 | Mary E. Bellizzi; David A. Betebenner; Jean-Christophe C. Califano; William A. Carroll; Daniel D. Caspi; David A. DeGoey; Pamela L. Donner; Charles A. Flentge; Yi Gao; Charles W. Hutchins; Douglas K. Hutchinson; Tammie K. Jinkerson; Warren M. Kati; Ryan G. Keddy; Allan C. Krueger; Wenke Li; Dachun Liu; Clarence J. Maring; Mark A. Matulenko; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; John K. Pratt; John T. Randolph; Todd W. Rockway; Kathy Sarris; Michael D. Tufano; Seble H. Wagaw; Rolf Wagner; Kevin R. Woller |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 63 | 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)- 2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS | US15316312 | 2014-06-04 | US20170145004A1 | 2017-05-25 | Gabriele AMARI; Elisabetta ARMANI; Mauro RICCABONI; Charles BAKER-GLENN |
| The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. | ||||||
| 64 | Anti-viral compounds | US14558318 | 2014-12-02 | US09586978B2 | 2017-03-07 | Mary E. Bellizzi; David A. Betebenner; Jean C. Califano; William A. Carroll; Daniel D. Caspi; David A. DeGoey; Pamela L. Donner; Charles A. Flentge; Yi Gao; Charles W. Hutchins; Douglas K. Hutchinson; Tammie K. Jinkerson; Warren M. Kati; Ryan G. Keddy; Allan C. Krueger; Wenke Li; Dachun Liu; Clarence J. Maring; Mark A. Matulenko; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; John K. Pratt; John T. Randolph; Todd W. Rockway; Kathy Sarris; Michael D. Tufano; Seble H. Wagaw; Rolf Wagner; Kevin R. Woller |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 65 | Methods and compositions for preparing and purifying noribogaine | US14298534 | 2014-06-06 | US09394294B2 | 2016-07-19 | Deborah C. Mash; Richard D. Gless, Jr. |
| Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine. | ||||||
| 66 | INDOLE AND BENZOFURAN FUSED ISOQUINUCLIDENE DERIVATIVES AND PROCESSES FOR PREPARING THEM | US14873417 | 2015-10-02 | US20160024075A1 | 2016-01-28 | Robert M. Moriarty |
| Provided herein are indole and benzofuran fused isoquinuclidene derivatives. Also provided herein are processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (−) and (+) noribogaine or a salt thereof, in substantially enantiomerically pure forms. | ||||||
| 67 | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them | US13749593 | 2013-01-24 | US09150584B2 | 2015-10-06 | Robert M. Moriarty |
| Provided herein are indole and benzofuran fused isoquinuclidene derivatives. Also provided herein are processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (−) and (+) noribogaine or a salt thereof, in substantially enantiomerically pure forms. | ||||||
| 68 | Anti-Viral Compounds | US14558318 | 2014-12-02 | US20150087618A1 | 2015-03-26 | Mary E. Bellizzi; David A. Betebenner; Jean C. Califano; William A. Carroll; Daniel D. Caspi; David A. DeGoey; Pamela L. Donner; Charles A. Flentge; Yi Gao; Charles W. Hutchins; Douglas K. Hutchinson; Tammie K. Jinkerson; Warren M. Kati; Ryan G. Keddy; Allan C. Krueger; Wenke Li; Dachun Liu; Clarence J. Maring; Mark A. Matulenko; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; John K. Pratt; John T. Randolph; Todd W. Rockway; Kathy Sarris; Michael D. Tufano; Seble H. Wagaw; Rolf Wagner; Kevin R. Woller |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 69 | Anti-viral compounds | US13100827 | 2011-05-04 | US08937150B2 | 2015-01-20 | David A. DeGoey; Warren M. Kati; Charles W. Hutchins; Pamela L. Donner; Allan C. Krueger; John T. Randolph; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; Mark A. Matulenko; Ryan G. Keddy; Tammie K. Jinkerson; Yi Gao; Dachun Liu; John K. Pratt; Todd W. Rockway; Clarence J. Maring; Douglas K. Hutchinson; Charles A. Flentge; Rolf Wagner; Michael D. Tufano; David A. Betebenner; Kathy Sarris; Kevin R. Woller; Seble H. Wagaw; Jean C. Califano; Wenke Li; Daniel D. Caspi; Mary E. Bellizzi; William A. Carroll |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 70 | METHODS AND COMPOSITIONS FOR PREPARING AND PURIFYING NORIBOGAINE | US14298534 | 2014-06-06 | US20140357741A1 | 2014-12-04 | Deborah C. Mash; Richard D. Gless, JR. |
| Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine. | ||||||
| 71 | Aminopyrazines as ATR kinase inhibitors | US13440981 | 2012-09-04 | US08877759B2 | 2014-11-04 | Jean-Damien Charrier; David Kay; Somhairle MacCormick; Pierre-Henri Storck; Joanne Pinder; Michael Edward O'Donnell; Ronald Marcellus Alphonsus Knegtel; Stephen Clinton Young; Philip Michael Reaper; Steven John Durrant; Heather Clare Twin; Christopher John Davis |
| The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein. | ||||||
| 72 | Compounds for the Treatment of Hepatitis C | US13798286 | 2013-03-13 | US20130197012A1 | 2013-08-01 | Kap-Sun Yeung; Kyle E. Parcella; John A. Bender; Brett R. Beno; Katharine A. Grant-Young; Ying Han; Piyasena Hewawasam; John F. Kadow; Andrew Nickel |
| The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | ||||||
| 73 | Compounds for the Treatment of Hepatitis C | US13588316 | 2012-08-17 | US20120316126A1 | 2012-12-13 | Kap-Sun Yeung; Kyle E. Parcella; John A. Bender; Brett R. Beno; Katharine A. Grant-Young; Ying Han; Piyasena Hewawasam; John F. Kadow; Andrew Nickel |
| The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | ||||||
| 74 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | US13371786 | 2012-02-13 | US20120201783A1 | 2012-08-09 | Kap-Sun Yeung; Kyle E. Parcella; John A. Bender; Brett R. Beno; Katharine A. Grant-Young; Ying Han; Piyasena Hewawasam; John F. Kadow; Andrew Nickel |
| The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | ||||||
| 75 | Antibacterial agents | US12563697 | 2009-09-21 | US08153843B2 | 2012-04-10 | Niels H. Andersen; Jason Bowman; Alice L. Erwin; Eric A. Harwood; Toni Kline; Khisimuzi E. Mdluli; Simon Ng; Keith B. Pfister; Ribhi Shawar; Allan S. Wagman; Asha Yabannavar |
| Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds. | ||||||
| 76 | Antibacterial agents | US11981279 | 2007-10-31 | US08101640B2 | 2012-01-24 | Niels H. Andersen; Jason Bowman; Alice Erwin; Eric Harwood; Toni Kline; Khisimuzi Mdluli; Simon Ng; Keith B. Pfister; Ribhi Shawar; Allan S. Wagman; Asha Yabannavar |
| Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds. | ||||||
| 77 | Anti-Viral Compounds | US13100827 | 2011-05-04 | US20120004196A1 | 2012-01-05 | David A. DeGoey; Warren M. Kati; Charles W. Hutchins; Pamela L. Donner; Allan C. Krueger; John T. Randolph; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; Mark A. Matulenko; Ryan G. Keddy; Tammie K. Jinkerson; Yi Gao; Dachun Liu; John K. Pratt; Todd W. Rockway; Clarence J. Maring; Douglas K. Hutchinson; Charles A. Flentge; Rolf Wagner; Michael D. Tufano; David A. Betebenner; Kathy Sarris; Kevin R. Woller; Seble H. Wagaw; Jean C. Califano; Wenke Li; Daniel D. Caspi; Mary E. Bellizzi; William A. Carroll |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 78 | Antibacterial agents | US11928122 | 2007-10-30 | US08084615B2 | 2011-12-27 | Niels H. Andersen; Jason Bowman; Alice L. Erwin; Eric A. Harwood; Toni Kline; Khisimuzi E. Mdluli; Simon Ng; Keith B. Pfister; Ribhi Shawar; Allan S. Wagman; Asha Yabannavar |
| Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds. | ||||||
| 79 | Opioid and opioid-like compounds and uses thereof | US12400344 | 2009-03-09 | US08017622B2 | 2011-09-13 | Edwin S. C. Wu; Mao-Hsiung Yen |
| The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage. | ||||||
| 80 | Anti-Viral Compounds | US12813301 | 2010-06-10 | US20100317568A1 | 2010-12-16 | David A. DeGoey; Warren M. Kati; Charles W. Hutchins; Pamela L. Donner; Allan C. Krueger; John T. Randolph; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; Mark A. Matulenko; Ryan G. Keddy; Tammie K. Jinkerson; Todd N. Soltwedel; Dachun Liu; John K. Pratt; Todd W. Rockway; Clarence J. Maring; Douglas K. Hutchinson; Charles A. Flentge; Rolf Wagner; Michael D. Tufano; David A. Betebenner; Michael J. Lavin; Kathy Sarris; Kevin R. Woller; Seble H. Wagaw; Jean C. Califano; Wenke Li; Daniel D. Caspi; Mary E. Bellizzi |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
QQ群二维码
意见反馈
意见反馈